# A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

> **NCT05375136** · — · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 135 (actual)

## Conditions studied

- Endometrial Neoplasms
- Endometrium
- Carcinoma
- Renal Cell Carcinoma

## Interventions

- **OTHER:** Non-interventional

## Key facts

- **NCT ID:** NCT05375136
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-25
- **Primary completion:** 2023-11-07
- **Final completion:** 2023-11-07
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375136, "A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05375136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*